Silkenstedt E, Dreyling M
Department of Medicine III, LMU Hospital, Munich, Germany.
Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70073. doi: 10.1002/hon.70073.
The development and implementation of new targeted and immunotherapeutic approaches in the treatment landscape of mantle cell lymphoma have already improved therapeutic options especially for refractory or relapsed disease. Regarding first-line therapy, treatment strategies including novel agents are under investigation. In transplant-eligible patients, a combined ibrutinib-containing immunochemotherapy induction followed by ASCT was shown to be superior compared to the chemotherapy regimen +/- ASCT. Thus, we consider the addition of ibrutinib to first-line therapy in younger MCL patients a new standard of care. For the group of older MCL patients ineligible for high-dose therapy and ASCT, several targeted therapy approaches have been investigated in different studies in combination with immunochemotherapies or as single agents +/- other targeted therapies with promising results. This review summarizes the current standard of care for first-line treatment of mantle cell lymphoma, highlighting the implementation of targeted treatment strategies, especially BTKi, in initial treatment strategies. Trial Registration: ClinicalTrials.gov identifier: NCT06482684.
在套细胞淋巴瘤的治疗领域，新的靶向治疗和免疫治疗方法的开发与应用已经改善了治疗选择，尤其是对于难治性或复发性疾病。关于一线治疗，包括新型药物的治疗策略正在研究中。在适合移植的患者中，与化疗方案±自体造血干细胞移植（ASCT）相比，含伊布替尼的联合免疫化疗诱导后行ASCT显示出优势。因此，我们认为在年轻套细胞淋巴瘤患者的一线治疗中添加伊布替尼是一种新的标准治疗方法。对于不符合高剂量治疗和ASCT条件的老年套细胞淋巴瘤患者，在不同研究中已经对几种靶向治疗方法与免疫化疗联合或作为单药±其他靶向治疗进行了研究，结果令人鼓舞。本综述总结了套细胞淋巴瘤一线治疗的当前标准治疗方法，强调了靶向治疗策略，尤其是布鲁顿酪氨酸激酶抑制剂（BTKi）在初始治疗策略中的应用。试验注册：ClinicalTrials.gov标识符：NCT06482684。
